Skip to main content

PERSPECTIVE article

Front. Aging
Sec. Cellular Senescence
Volume 6 - 2025 | doi: 10.3389/fragi.2025.1505063
This article is part of the Research Topic Resilience in Aging View all 5 articles

Inhibition of miMOMP-induced SASP to combat age-related disease

Provisionally accepted
Xiaoli Liao Xiaoli Liao 1Zhennan Guo Zhennan Guo 2Mouhai He Mouhai He 1Yichun Zhang Yichun Zhang 1*
  • 1 Hunan Institute of Traffic Engineering, Hengyang, China
  • 2 Hengyang Xin yahan medical beauty clinic, Hengyang, China

The final, formatted version of the article will be published soon.

    Cellular senescence, first described in 1961, was initially observed in normal human fibroblasts that ceased proliferating to proliferate in culture after a finite number of divisions in culture (Hayflick and Moorhead, 1961). Cellular senescence is a cell state This process is triggered by various stimuli, including oxidative stress, chromatin modifications and oncogene activation, characterized by an irreversible cellcycle arrest, apoptosis resistance to apoptosis and an the induction of a complex senescent associated secretory phenotype (SASP) (Calabrò et al., 2024). Over the last past decade, emerging evidence has revealed thatlinked cellular senescence is implicated in to the aging process and associated with a wide range of chronic age-related diseases (Calabrò et al., 2024). As suchConsequently, research focused on targeting senescence to alleviate or delay age-related disease, also knownreferred to as senotherapy, has been conducted rapidly. Therefore, elucidating the mechanisms of cellular senescence is essential to providefor providing practical strategies for the development of drugs targetingaimed at addressing this condition.

    Keywords: miMOMP, SASP (senescence-associated secretory phenotype), age-related disease, cGAS-STING, mtDNA

    Received: 02 Oct 2024; Accepted: 15 Jan 2025.

    Copyright: © 2025 Liao, Guo, He and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Yichun Zhang, Hunan Institute of Traffic Engineering, Hengyang, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.